Screener
Vor Biopharma VOR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Repurchases of shares for tax withholdings upon vesting of restricted stock unit awards | (2) | (55) |
| Proceeds from issuance of common stock in private placement | 74,999 | — |
| Net cash provided by (used in) financing activities | 74,870 | (606) |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (226,613) | (31,902) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | $396,654 | $84,362 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $170,041 | $52,460 |
| Supplemental disclosure of non-cash activities | ||
| Purchases of property and equipment in accounts payable and accrued liabilities | $12 | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's net change in cash?
- Vor Biopharma (VOR) reported net change in cash of -$226.61M in Q1 2026.
- How has Vor Biopharma's net change in cash changed year-over-year?
- Vor Biopharma's net change in cash decreased by 610.3% year-over-year, from -$31.9M to -$226.61M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Vor Biopharma's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude